Open AccessVGF Expression by Monocytes in Patients with Alzheimer’s Disease and Vascular Dementia
Author(s) -
Stefan Busse,
Eva Meyer,
Henrik Dobrowolny,
Christian Mawrin,
Roland Hartig,
Bernhard Bogerts,
Mandy Busse
Publication year - 2022
Publication title -
geropsych
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.417
H-Index - 19
eISSN - 1662-971X
pISSN - 1662-9647
DOI - 10.1024/1662-9647/a000263
Subject(s) - vascular dementia , dementia , medicine , cd14 , biomarker , flow cytometry , peripheral , alzheimer's disease , monocyte , immunology , peripheral blood , disease , vascular disease , pathology , biology , biochemistry
. Because its secretion is changed in cerebrospinal fluid and peripheral blood, the neuronal polypeptide VGF (nonacronymic) has been discussed as a biomarker for neuropsychiatric disorders. We have shown an enhanced VGF expression by T-cells from Alzheimer’s disease (AD) patients. In this study, we investigated the VGF expression by peripheral monocytes in 38 AD patients, 5 patients with vascular dementia (VD), and 20 neuropsychiatrically healthy individuals using flow cytometry. We determined an enhanced number of VGF-expressing monocytes in VD patients compared to AD patients. VGF+CD14+ monocytes were not correlated with age, body mass index, Mini-Mental State Examination (MMSE), or Q albumin. These preliminary data support findings indicating that VGF might play a role as a peripheral biomarker in VD.